FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options.
Gibson called for more funds to be allocated for mobile units to care for drug users in the Bronx; Naloxone training for residents and caregivers; and an ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...